A popular blood pressure medication has been withdrawn from the market due to concerns about potential contamination with another drug.

Over 11,100 bottles of Ziac, which contains bisoprolol fumarate and hydrochlorothiazide tablets, have been recalled by Glenmark Pharmaceuticals Inc in the United States. The recall notice issued by the Food and Drug Administration states that the tablets might have been tainted by other substances.

These tablets are commonly prescribed to manage hypertension by blocking beta-1 receptors in the heart, helping to regulate the heartbeat, as per information from WebMD.

The recall notice reveals that testing found the presence of ezetimibe, a drug used for high cholesterol treatment. The FDA classified the December 1 recall as Class III, indicating that it is unlikely to cause severe health issues upon use or exposure.

The impacted pills are available in 2.5mg and 6.25mg doses, with specific package sizes including 30-count bottles NDC-68462-878-30, 100-count bottles NDC-68462-878-01, and 500-count bottles NDC-68462-878-05.

The affected lot numbers have expiration dates ranging from November 2025 to May 2026, with a total of 11,136 bottles being affected by the recall. The FDA has not yet provided guidance on what actions patients should take if their medication falls under the recall.